AU2019234759C1 - O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors - Google Patents
O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors Download PDFInfo
- Publication number
- AU2019234759C1 AU2019234759C1 AU2019234759A AU2019234759A AU2019234759C1 AU 2019234759 C1 AU2019234759 C1 AU 2019234759C1 AU 2019234759 A AU2019234759 A AU 2019234759A AU 2019234759 A AU2019234759 A AU 2019234759A AU 2019234759 C1 AU2019234759 C1 AU 2019234759C1
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- alkyl
- methyl
- halo
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642932P | 2018-03-14 | 2018-03-14 | |
| US62/642,932 | 2018-03-14 | ||
| US201862690536P | 2018-06-27 | 2018-06-27 | |
| US62/690,536 | 2018-06-27 | ||
| US201862699443P | 2018-07-17 | 2018-07-17 | |
| US62/699,443 | 2018-07-17 | ||
| PCT/US2019/021995 WO2019178191A1 (en) | 2018-03-14 | 2019-03-13 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2019234759A1 AU2019234759A1 (en) | 2020-09-17 |
| AU2019234759B2 AU2019234759B2 (en) | 2024-08-01 |
| AU2019234759C1 true AU2019234759C1 (en) | 2025-02-06 |
Family
ID=65952097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019234759A Active AU2019234759C1 (en) | 2018-03-14 | 2019-03-13 | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230117898A1 (enExample) |
| EP (2) | EP3765458B1 (enExample) |
| JP (1) | JP7453916B2 (enExample) |
| CN (2) | CN112218863B (enExample) |
| AU (1) | AU2019234759C1 (enExample) |
| CA (1) | CA3093315A1 (enExample) |
| ES (1) | ES2942211T3 (enExample) |
| MA (1) | MA52004A (enExample) |
| MX (1) | MX2020009530A (enExample) |
| WO (1) | WO2019178191A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018154133A1 (en) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| US12180205B2 (en) * | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| WO2021094312A1 (en) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds |
| WO2021110656A1 (en) | 2019-12-02 | 2021-06-10 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| US20230058733A1 (en) | 2019-12-18 | 2023-02-23 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| CN114867725A (zh) | 2019-12-18 | 2022-08-05 | 詹森药业有限公司 | Oga抑制剂化合物 |
| WO2021123291A1 (en) | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| CN114213315A (zh) * | 2021-12-31 | 2022-03-22 | 上海陶术生物科技有限公司 | 含氮杂环类化合物及其中间体的合成方法 |
| CN114560805B (zh) * | 2022-01-20 | 2024-11-29 | 上海陶术生物科技有限公司 | 含氮杂环化合物及其中间体的合成方法 |
| WO2026021588A1 (zh) * | 2024-07-26 | 2026-01-29 | 浙江同源康医药股份有限公司 | Oga抑制剂及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159234A1 (en) * | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | Glycosidase inhibitors |
| WO2017106254A1 (en) * | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| WO2018109198A1 (en) * | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
| WO2018154133A1 (en) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3555087A1 (en) * | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
-
2019
- 2019-03-13 JP JP2020548963A patent/JP7453916B2/ja active Active
- 2019-03-13 MX MX2020009530A patent/MX2020009530A/es unknown
- 2019-03-13 WO PCT/US2019/021995 patent/WO2019178191A1/en not_active Ceased
- 2019-03-13 EP EP19713945.4A patent/EP3765458B1/en active Active
- 2019-03-13 CA CA3093315A patent/CA3093315A1/en active Pending
- 2019-03-13 ES ES19713945T patent/ES2942211T3/es active Active
- 2019-03-13 CN CN201980019170.5A patent/CN112218863B/zh active Active
- 2019-03-13 AU AU2019234759A patent/AU2019234759C1/en active Active
- 2019-03-13 CN CN202410813893.5A patent/CN118955490A/zh active Pending
- 2019-03-13 EP EP23151036.3A patent/EP4186899A1/en active Pending
- 2019-03-13 MA MA052004A patent/MA52004A/fr unknown
-
2022
- 2022-08-24 US US17/894,461 patent/US20230117898A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159234A1 (en) * | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | Glycosidase inhibitors |
| WO2017106254A1 (en) * | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| WO2018109198A1 (en) * | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
| WO2018154133A1 (en) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021518340A (ja) | 2021-08-02 |
| CN112218863A (zh) | 2021-01-12 |
| US20230117898A1 (en) | 2023-04-20 |
| EP4186899A1 (en) | 2023-05-31 |
| ES2942211T3 (es) | 2023-05-30 |
| AU2019234759B2 (en) | 2024-08-01 |
| MX2020009530A (es) | 2021-01-15 |
| CA3093315A1 (en) | 2019-09-19 |
| AU2019234759A1 (en) | 2020-09-17 |
| JP7453916B2 (ja) | 2024-03-21 |
| WO2019178191A1 (en) | 2019-09-19 |
| CN112218863B (zh) | 2024-07-12 |
| EP3765458A1 (en) | 2021-01-20 |
| CN118955490A (zh) | 2024-11-15 |
| MA52004A (fr) | 2021-01-20 |
| WO2019178191A8 (en) | 2019-12-26 |
| EP3765458B1 (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019234759C1 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors | |
| US10689368B2 (en) | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | |
| JP7577655B2 (ja) | 環状尿素 | |
| KR20220125306A (ko) | RORγt 억제제, 이의 제조 방법 및 이의 용도 | |
| CA3226796A1 (en) | Novel parp7 inhibitor and use thereof | |
| EP3891146B1 (en) | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl derivatives useful as o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| US11459324B2 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors | |
| JP7663503B2 (ja) | アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 | |
| HK40046057B (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors | |
| HK40046057A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors | |
| CA3207069A1 (en) | Compounds and methods for modulating fxr | |
| CA3202165A1 (en) | Heterocyclic derivatives as p2x7 receptor antagonists | |
| JP2023509496A (ja) | ＲＯＲγｔ阻害剤、その製造方法及び使用 | |
| HK1165418B (en) | Azetidines as histamine h3 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 OCT 2024 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 31 OCT 2024 |
|
| FGA | Letters patent sealed or granted (standard patent) |